X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer
CAMBRIDGE, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the promotion of …